News stories about Biogen (NASDAQ:BIIB) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Biogen earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.3165745516417 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- Biogen (BIIB) Upgraded to Buy at Credit Suisse Group (americanbankingnews.com)
- BRIEF-Biogen Reports Top-Line Results From Phase 2b Study Of Natalizumab In Acute Ischemic Stroke (reuters.com)
- Biogen Halts Tysabri Development in Stroke as Study Fails (finance.yahoo.com)
- Exploring Bioverativ’s Business Profile and Market Presence (finance.yahoo.com)
- Biogen's Tysabri Fails In Stroke Trial — Coming As 'No Surprise' (finance.yahoo.com)
Several research firms have recently weighed in on BIIB. Canaccord Genuity reaffirmed a “hold” rating and set a $350.00 price objective on shares of Biogen in a research report on Wednesday. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Biogen in a report on Thursday. Oppenheimer upped their target price on Biogen from $380.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, January 26th. Mizuho reiterated a “buy” rating and set a $433.00 target price (up previously from $400.00) on shares of Biogen in a report on Sunday, February 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $363.00 target price (up previously from $340.00) on shares of Biogen in a report on Friday, January 26th. Eight equities research analysts have rated the stock with a hold rating and twenty-four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $368.99.
Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $5.44 by ($0.18). The company had revenue of $3.31 billion for the quarter, compared to analyst estimates of $3.08 billion. Biogen had a return on equity of 38.32% and a net margin of 20.69%. The company’s quarterly revenue was up 15.1% compared to the same quarter last year. During the same period in the prior year, the company earned $5.04 EPS. sell-side analysts predict that Biogen will post 24.88 EPS for the current fiscal year.
In other Biogen news, Director Alexander J. Denner bought 30,000 shares of Biogen stock in a transaction on Wednesday, November 29th. The shares were purchased at an average price of $317.36 per share, with a total value of $9,520,800.00. Following the acquisition, the director now owns 10,029 shares in the company, valued at approximately $3,182,803.44. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert W. Pangia sold 5,832 shares of the firm’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $329.65, for a total value of $1,922,518.80. Following the completion of the sale, the director now directly owns 23,539 shares in the company, valued at approximately $7,759,631.35. The disclosure for this sale can be found here. In the last ninety days, insiders acquired 31,560 shares of company stock worth $10,020,858. Company insiders own 0.25% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Biogen (BIIB) Getting Somewhat Favorable Media Coverage, Report Finds” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://stocknewstimes.com/2018/02/11/biogen-biib-receives-daily-media-impact-rating-of-0-18.html.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.